Patent intelligence · US
US 11344626
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
Patent details — US 11344626
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 31, 2022
- Expiration
- May 26, 2042
- Applicant
- Sutro Biopharma, Inc.
- Claims
- 39
- CPC classes
- A61K, A61K2039/505, A61K47/6803, A61K47/68031
Quick answer
US 11344626 (Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use) is held by Sutro Biopharma, Inc.. Status: granted. Granted May 31, 2022. Expires May 26, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sutro Biopharma, Inc.
- Grant date
- Expiration
- Claims
- 39
- CPC classes
- A61K, A61K2039/505, A61K47/6803, A61K47/68031, A61K47/68033, A61K47/68035
More from Sutro Biopharma, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427201
Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
granted -
US 12398197
Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
granted -
US 12351850
Methods of producing full-length antibodies using E. coli
granted -
US 12269801
Modified amino acids
granted -
US 12252552
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
granted -
US 12226490
Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary class
granted -
US 12144869
Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates
granted -
US 12071477
Anti-folate receptor alpha antibody conjugated with hemiasterlins
granted
Frequently asked questions
What is US patent 11344626?
US 11344626 (Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use) is held by Sutro Biopharma, Inc.. Status: granted. Granted May 31, 2022. Expires May 26, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11344626?
Sutro Biopharma, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.
When does US 11344626 expire?
Our index shows an expiration date of May 26, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.